Nosatel (Dexketoprofen)

Dexketoprofen blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for the production of prostaglandins. By reducing prostaglandin synthesis, it lowers inflammation, pain signalling, and fever, resulting in fast‑acting analgesic and anti‑inflammatory effects at the site of injury.

The specific dose and frequency of Nosatel are determined by the prescribing clinician based on the severity of pain, the patient’s clinical condition, and the route of administration. Healthcare professionals adjust the regimen to achieve effective pain control while minimising risk.

Safety data for dexketoprofen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To order Nosatel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Nosatel (dexketoprofen) is a potent NSAID with a rapid onset of action compared with traditional ketoprofen or ibuprofen. Its enantiomeric form often provides effective pain relief at lower doses, potentially reducing gastrointestinal side‑effects, though it shares the class‑related risks of renal and cardiovascular events.

Nosatel should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures. Do not freeze the solution, and ensure that vials are kept upright to avoid agitation before use.

Nosatel is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) administration. The injection is performed by a qualified healthcare professional using aseptic technique, with the dose and route selected according to the patient’s clinical needs and the prescriber’s instructions.

Serious risks include gastrointestinal ulceration or bleeding, renal impairment, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should be monitored for signs of these events, especially if they have a history of ulcer disease, kidney problems, or are taking interacting medications.

Nosatel is contraindicated in patients with known hypersensitivity to dexketoprofen or any NSAID, those with active gastrointestinal bleeding or ulcer, severe renal or hepatic impairment, and in individuals who have experienced severe cardiovascular events related to NSAID use. A healthcare professional should evaluate suitability before prescribing.